Bull & Bear

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — the quality is real, but at 72× trailing P/E the premium is paying for cash flow that one-time working-capital movements lifted, for a 14-molecule book a closer peer outprints 2.4×, and for governance scaffolding (DavosPharma, Neoanthem, upside-sharing payout) that any disciplined buyer would discount. Bull's capital-productivity case is the strongest fact in the file — 43.4% EBITDA margin and 31.7% ROCE that no listed Indian CRDMO peer touches — but Bear has identified specific, testable items that should compress the multiple before this is ownable. The tension that matters most is FY26 margin durability: the same 43.4% number is "structural" to Bull and "lifted by inventory-days collapse plus $4.4M of forex/RoDTEP" to Bear, and only the FY27 print resolves it. Two pieces of evidence flip this verdict to Lean Long: (a) two consecutive FY27 quarters with EBITDA margin at or above 40% after the cash-conversion cycle normalises back toward 150 days, and (b) Aragen Life Sciences listing at a multiple that confirms — not compresses — the listed-CRDMO median.

Bull Case

Bull targets $11.40 per share, roughly 41% upside from $8.06, via ~65× FY28E EPS of ~$0.18 — FY28 PAT of ~$101 mn on 18% revenue CAGR (FY26 $219 mn → FY28 $305 mn) at 41% sustained EBITDA and 28% PAT margin on 561.8 mn shares. 65× FY28 is below Anthem's own 74× trailing and broadly in line with Sai Life's ~69×. Timeline is 18 months through November 2027. The disconfirming signal Bull names is a single USFDA Form 483 with significant observations at Unit I or II, or trailing-twelve-month EBITDA margin below 38% for two consecutive quarters.

Bear Case

Bear targets $5.06 per share, 37% downside from $8.06, via 50× P/E (Indian listed-CRDMO median ex-Divi's) applied to FY27E EPS of ~$0.10 — assuming 12% revenue growth (below management's already-cut mid-teens guide), net margin reverting to 22% on Unit-4 ramp dilution, working-capital normalisation, and roll-off of FY26 forex/RoDTEP. Timeline is 12-18 months. The cover signal Bear names is two consecutive quarters of EBITDA margin above 42% after the working-capital tailwind reverses (CCC back to 150+ days, payable days back to 50+) and a Q4 FY27 disclosure showing six or more new commercial-molecule net adds.

The Real Debate

Verdict

Watchlist. Bear carries marginally more weight today, not because the business is bad — it is the cleanest capital-productivity profile in the listed Indian CRDMO peer set — but because the price-supporting fact (the FY26 cash-flow and margin step-up) depends on a working-capital movement Bear has shown is non-repeatable, and the multiple paying for that step-up is the highest in the peer set on the second-deepest commercial book. The decisive tension is FY26 margin durability: 43.4% EBITDA at face value is structural quality, but after stripping $4.4M of forex/RoDTEP it is the FY24 trough, and the FY27 print is the only thing that resolves it. Bull could still be right — backward integration on semaglutide is permanent, the 4-molecule net add is the best five-year print, and promoter-group ownership of 74.67% is alignment no peer matches — which is why this is Watchlist rather than Avoid. The durable thesis-flipper is two consecutive FY27 quarters with EBITDA margin at or above 40% after the cash-conversion cycle normalises back toward 150 days; the near-term evidence marker is the Aragen IPO pricing, since it sets the listed-CRDMO median Anthem's premium has to live above. Until at least one of those resolves, paying 72× trailing for governance scaffolding that includes DavosPharma's 14.28% revenue conduit outside the audit-committee firewall, Neoanthem intercompany loans at 11.7% of assets, and a $13.6M upside-sharing payout is the kind of premium a disciplined buyer waits to be paid for, not pays for.